William Blair analyst Matt Phipps maintained a Hold rating on Kezar Life Sciences (KZR – Research Report) today. The company’s shares closed ...

Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...

Research analysts at William Blair increased their Q2 2025 earnings per share estimates for shares of BJ’s Restaurants in a note issued to investors on Friday, February 21st. William Blair analyst S.

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...

William Blair downgrades Booz Allen, CACI International, Leidos, Parsons and General Dynamics on the heightened risk of ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

William Blair downgraded Booz Allen (BAH) to Market Perform from Outperform.Discover the Best Stocks and Maximize Your Portfolio: See what ...

Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...

Repligen Corp (NASDAQ:RGEN) released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago ...

William Blair International Growth Fund earns an Average Process Pillar rating. The main driver of the rating is the fund's excellent long-term risk-adjusted performance. This can be seen in its ...